Currently, there are 160.48M common shares owned by the public and among those 55.17M shares have been available to trade.
The company’s stock has a 5-day price change of -78.11% and -83.20% over the past three months. NMRA shares are trading -76.60% year to date (YTD), with the 12-month market performance down to -84.87% lower. It has a 12-month low price of $1.83 and touched a high of $21.00 over the same period. NMRA has an average intraday trading volume of 2.15 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -73.68%, -76.16%, and -77.96% respectively.
Institutional ownership of Neumora Therapeutics Inc (NASDAQ: NMRA) shares accounts for 29.80% of the company’s 160.48M shares outstanding.
It has a market capitalization of $441.35M and a beta (3y monthly) value of 3.21. The earnings-per-share (ttm) stands at -$1.85. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.77% over the week and 9.13% over the month.
Earnings per share for the fiscal year are expected to increase by 55.97%, and -0.72% over the next financial year.
Looking at the support for the NMRA, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on January 02, 2025, with the firm’s price target at $29-$4. JP Morgan coverage for the Neumora Therapeutics Inc (NMRA) stock in a research note released on November 05, 2024 offered a Neutral rating with a price target of $15. H.C. Wainwright was of a view on October 01, 2024 that the stock is Buy, while Needham gave the stock Buy rating on July 22, 2024, issuing a price target of $23. Mizuho on their part issued Outperform rating on July 08, 2024.
